Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21015427 | 0.93 | ADORA3 (0.52) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL31228106 | 0.89 | ADORA3 (0.52) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL21016259 | 0.89 | P2RY1 (0.42) | ADORA3ADORA1ADORA2BHTR2CHTR2B | |
| SCHEMBL19859703 | 0.88 | ADORA2A (0.46) | ADORA3ADORA1AHCYADORA2A | |
| SCHEMBL21015441 | 0.85 | P2RY1 (0.47) | ADORA3ADORA1ADORA2B | |
| SCHEMBL19778486 | 0.84 | HTR2C (0.41) | ADORA3ADORA1PGK1PGK2HTR2C | |
| SCHEMBL16647595 | 0.83 | ADORA2A (0.39) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL21015753 | 0.83 | P2RY1 (0.50) | ADORA3ADORA1ADORA2B | |
| SCHEMBL19778361 | 0.82 | ADORA3 (0.45) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL19777952 | 0.82 | ADORA2A (0.36) | ADORA3ADORA1ADORA2BPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | ADORA3 27/4885ADORA1 34/4885ADORA2B 30/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | ADORA3 27/4885ADORA1 31/4885ADORA2B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.